ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

VICTOZA
Diabetes
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

VICTOZA Rx

Generic Name and Formulations:
Liraglutide 6mg/mL; soln for SC inj.

Company:
Novo Nordisk

premium monograph ?Access to resources provided by Novo Nordisk Medical Affairs
Search for comprehensive medical information for VICTOZA
Search Premium Monographs

Have a product inquiry? Access comprehensive and accurate pharmaceutical Medical Information

Therapeutic Use:

Indications for VICTOZA:

As adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus (T2DM). To reduce the risk of major adverse CV events (eg, CV death, non-fatal MI/stroke) in adults with T2DM and established CV disease.

Limitations Of use:

Not a substitute for insulin. Not for treating type 1 diabetes or diabetic ketoacidosis. Not studied in combination with prandial insulin.

Adult:

Give by SC inj in abdomen, thigh, or upper arm once daily. Initially 0.6mg/day for 1 week, then 1.2mg/day; may increase to 1.8mg/day. If >3 days elapsed since last dose, reinitiate at 0.6mg/day, then titrate.

Children:

<18yrs: not recommended.

Contraindications:

History (personal or family) of medullary thyroid carcinoma. Multiple endocrine neoplasia syndrome type 2.

Boxed Warning:

Risk of thyroid C-cell tumors.

Warnings/Precautions:

Risk of thyroid C-cell tumors; inform patients of potential risk and symptoms. Discontinue if pancreatitis is suspected; do not restart if confirmed. History of pancreatitis: limited data. Evaluate if cholelithiasis is suspected. Do not reuse or share pens or needles between patients. History of anaphylaxis or angioedema with other GLP-1 receptor agonist. Discontinue if hypersensitivity reactions occur. Renal impairment: caution with initiating or escalating doses. Hepatic impairment: use with caution (limited data). Dehydration. Gastroparesis: not studied. Pregnancy. Nursing mothers.

Thyroid Conditions Powered by Novo Nordisk Medical Affairs

The below information is supplied to you as a professional service in response to your specific request. This letter is meant to supplement information you have gathered from other sources and is not intended to promote or advocate the use of Novo Nordisk products in any manner other than described in the Prescribing Information.

Use of Victoza® in Patients With Pre-Existing Thyroid Conditions

Additional Information

References

Renal Impairment Powered by Novo Nordisk Medical Affairs

The below information is supplied to you as a professional service in response to your specific request. This letter is meant to supplement information you have gathered from other sources and is not intended to promote or advocate the use of Novo Nordisk products in any manner other than described in the Prescribing Information.

Summary

Clinical Trials of Victoza® in Patients with Renal Impairment

Independent Studies

Use in Patients Undergoing Hemodialysis

Meta-Analysis Across Phase 3 Studies6

Pharmacokinetic Studies

Additional Clinical Data

APPENDIX A

References

Pharmacological Class:

Glucagon-like peptide-1 (GLP-1) receptor agonist.

Interactions:

Concomitant insulin; administer as separate injections not adjacent to each other. Hypoglycemia with sulfonylureas or insulin (consider reducing their doses). May affect absorption of concomitant oral drugs (delayed gastric emptying); caution.

Adverse Reactions:

Nausea, diarrhea, headache, vomiting, decreased appetite, dyspepsia, constipation, immunogenicity reactions (eg, urticaria); rare: pancreatitis, papillary thyroid carcinoma, hypersensitivity reactions.

Generic Availability:

NO

How Supplied:

Multi-dose, pre-filled pens (3mL)—2, 3

Sign Up for Free e-newsletters